Apixaban News and Research

RSS

Anticoagulation lowers subclinical leaflet thrombosis after TAVI procedure

After transcatheter aortic valve implantation (TAVI), anticoagulation reduced imaging signs of clot formation on the new valve compared with antiplatelet therapy, without compromising safety. This was the main finding of the ACASA-TAVI trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in JAMA.

31 Aug 2026

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart attack.

29 Aug 2026

New findings do not support the use of edoxaban in AF patients after intracranial hemorrhage

Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial fibrillation who had had an intracranial hemorrhage, according to results presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

Oral anticoagulants benefit patients with atrial fibrillation at intermediate stroke risk

Oral anticoagulant therapy lowered the risk of adverse clinical events compared with no anticoagulation in patients with atrial fibrillation at intermediate stroke risk, according to results from the SINGLE-AF trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

28 Aug 2026

Apixaban reduces complications, helps older adults spend more time at home after blood clots

Older adults recovering from serious blood clots often face long periods of hospitalization or rehabilitation due to a higher rate of recurrence.

27 Apr 2026

Apixaban safer than rivaroxaban for treating venous thrombosis

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications.

11 Mar 2026

New guidelines outline comprehensive care for acute pulmonary embolism

Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life-threatening blood clot that blocks arteries in the lungs, is critical.

19 Feb 2026

Investigational anti-clotting drug reduces risk of second ischemic stroke without bleeding concerns

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary late-breaking science presentation at the American Stroke Association's International Stroke Conference 2026.

6 Feb 2026

One-month dual therapy strategy offers advantages for AFib patients and clinicians

New research found a simplified clot-preventing medication regimen following stent placement in adults with atrial fibrillation was just as safe and effective in preventing strokes, heart attack and death, when compared to a standard year-long treatment regimen, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Stopping oral anticoagulation reduces risk after successful atrial fibrillation ablation

Discontinuing oral anticoagulation (OAC) therapy resulted in a lower risk of a composite of stroke, systemic embolism or major bleeding than continuing OAC therapy in patients who had successful ablation for atrial fibrillation at least 12 months previously, according to results from a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in The Journal of the American Medical Association.

3 Sep 2025

Tailored risk-based treatment does not improve outcomes in atrial fibrillation

An individually tailored multidimensional risk-based treatment strategy was not associated with improvements in clinical outcomes compared with usual guideline-based care in patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Reduced-dose apixaban proves effective in preventing blood clot recurrence in cancer patients

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral blood-thinning medication over the same extended period.

29 Mar 2025

Medicare Part D beneficiaries face rising out-of-pocket costs for brand name drugs The Expe...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, according to new research from the USC Schaeffer Center for Health Policy & Economics published in JAMA.

19 Feb 2025

Study highlights risks of stopping anticoagulants in older patients

For patients with atrial fibrillation, the risk of stroke or heart attack from stopping anticoagulants usually outweighs the risk of bleeding, according to new findings from the University of Bath.

18 Feb 2025

Reduced blood thinner dose may lower bleeding risk and hospital visits

For people taking popular blood thinners after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.

19 Dec 2024

NSAIDs raise bleeding risk in patients taking blood thinners

People who take an anticoagulant medicine double their risk of an internal bleed if they take a type of painkiller called a non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen, diclofenac or naproxen, according to research published in the European Heart Journal [1] today (Monday).

18 Nov 2024